Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
- Registration Number
- NCT00446082
- Lead Sponsor
- Novartis Pharmaceuticals
- Brief Summary
This study will assess the pharmacokinetic profile and the safety/tolerability profile of single and monthly doses of pasireotide LAR intramuscular (i.m.) injection in patients with acromegaly and patients with carcinoid disease
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 85
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description SOM230 LAR Pasireotide -
- Primary Outcome Measures
Name Time Method Determination of the pharmacokinetic profile of single and monthly doses of pasireotide LAR i.m. injection Baseline, D7, D35, D63 in patients with acromegaly and in patients with carcinoid disease
- Secondary Outcome Measures
Name Time Method To explore the pharmacodynamic profile of single and monthly doses of pasireotide LAR i.m. injection Baseline, D7, D35, D63 in patients with acromegaly and in patients with carcinoid disease.
Trial Locations
- Locations (5)
Cedars Sinai Medical Center SC - 4
🇺🇸Los Angeles, California, United States
Stanford University Medical Center Stanford Cancer Center (3)
🇺🇸Stanford, California, United States
H. Lee Moffitt Cancer Center & Research Institute Dept.of H.LeeMoffittCC&RI(1)
🇺🇸Tampa, Florida, United States
University of Texas/MD Anderson Cancer Center Gastrointestinal Med. Oncology
🇺🇸Houston, Texas, United States
Novartis Investigative Site
🇳🇴Oslo, Norway
Cedars Sinai Medical Center SC - 4🇺🇸Los Angeles, California, United States